Dizal to unveil data on two new therapies at ELCC

Dizal Pharmaceutical (SHA: 688192) will present new research findings on two of its innovative drugs - sunvozertinib and golidacitinib - at the 2025 European Lung Cancer Congress (ELCC).

The studies focus on addressing resistance in non-small cell lung cancer (NSCLC) treatments. Sunvozertinib is a targeted therapy designed to address various mutations in the epidermal growth factor receptor (EGFR), which are often linked to resistance against existing treatments.

In a Phase II clinical trial, Sunvozertinib was combined with anlotinib, another targeted therapy, to treat patients with advanced NSCLC who had become resistant to prior EGFR therapies.  Among the 12 patients evaluated by December 25, 2024, one-third showed significant tumor reduction, and all experienced disease stabilization. The treatment was also generally well-tolerated.